<?xml version="1.0" encoding="UTF-8"?>
<ref id="CIT0016">
 <label>16</label>
 <mixed-citation publication-type="journal">
  <person-group person-group-type="author">
   <name name-style="western">
    <surname>Farag</surname>
    <given-names>AK</given-names>
   </name>, 
   <name name-style="western">
    <surname>Hassan</surname>
    <given-names>AHE</given-names>
   </name>, 
   <name name-style="western">
    <surname>Jeong</surname>
    <given-names>H</given-names>
   </name>, 
   <etal>et al.</etal>
  </person-group>
  <article-title>First-in-class DAPK1/CSF1R dual inhibitors: discovery of 3,5-dimethoxy-N-(4-(4-methoxyphenoxy)-2-((6-morpholinopyridin-3-yl)amino)pyrimidi n-5-yl)benzamide as a potential anti-tauopathies agent</article-title>. 
  <source>Eur J Med Chem</source>
  <year>2019</year>;
  <volume>162</volume>:
  <fpage>161</fpage>–
  <lpage>75</lpage>.,
  <pub-id pub-id-type="pmid">30445265</pub-id>
 </mixed-citation>
</ref>
